These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical uses of nalidixic acid analogues: the fluoroquinolones. Høiby N Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628 [No Abstract] [Full Text] [Related]
5. [Therapeutic contribution of the new quinolones]. Wolff M Rev Prat; 1987 Apr; 37(21):1209-14. PubMed ID: 3474759 [No Abstract] [Full Text] [Related]
6. Quinolones in the treatment of serious infections. Webster A; Gaya H Rev Infect Dis; 1988; 10 Suppl 1():S225-33. PubMed ID: 3279496 [TBL] [Abstract][Full Text] [Related]
7. Clinical use of the quinolones. Neu HC Lancet; 1987 Dec; 2(8571):1319-22. PubMed ID: 2890913 [No Abstract] [Full Text] [Related]
8. Quinolones. Shah PM Prog Drug Res; 1987; 31():243-56. PubMed ID: 3326031 [No Abstract] [Full Text] [Related]
9. [Fluoroquinolones]. Baykal M; Akalin E Mikrobiyol Bul; 1987 Apr; 21(2):151-7. PubMed ID: 3482120 [TBL] [Abstract][Full Text] [Related]
10. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline. Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Wise R; Griggs D; Andrews JM Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327 [TBL] [Abstract][Full Text] [Related]
12. [Gyrase inhibitors: unwanted central nervous system effects]. Rietbrock N; Staib AH Dtsch Med Wochenschr; 1987 Jan; 112(5):201. PubMed ID: 3467948 [No Abstract] [Full Text] [Related]
13. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B Infection; 1985; 13(5):219-24. PubMed ID: 2933340 [TBL] [Abstract][Full Text] [Related]
14. [Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs]. Naumann P; Dopp C Internist (Berl); 1989 Jan; 30(1):20-31. PubMed ID: 2646237 [No Abstract] [Full Text] [Related]
15. The comparative pharmacokinetics of five quinolones. Wise R; Lister D; McNulty CA; Griggs D; Andrews JM J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile. Edlund C; Nord CE Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556 [TBL] [Abstract][Full Text] [Related]
17. The adverse effects of fluoroquinolones. Smith CR J Antimicrob Chemother; 1987 Jun; 19(6):709-11. PubMed ID: 3475267 [No Abstract] [Full Text] [Related]
18. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Hooper DC; Wolfson JS Antimicrob Agents Chemother; 1985 Nov; 28(5):716-21. PubMed ID: 2936302 [No Abstract] [Full Text] [Related]